This study is for patients with stage II colon cancer who have undergone resection without evidence of metastatic disease, who are thinking about post-operative chemotherapy (adjuvant therapy)
Protocol number: E5202
Type of cancer: Stage II Colorectal Cancer
Phase number: III
Summary: This is a phase III study for patients who need adjuvant chemotherapy after surgery. Patients should have Stage II colon cancer. The study compares the effectiveness of standard treatment (FOLFOX) to the effectiveness of FOLFOX plus bevacizumab (Avastin), which is a monoclonal antibody that is thought to block the growth of some cancer cells.